Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
暂无分享,去创建一个
M. Vignetti | G. Leone | G. Meloni | X. Thomas | W. Feremans | S. Suciu | G. Fillet | S. Amadori | U. Jehn | B. Rio | T. de Witte | G. Broccia | T. D. de Witte
[1] F. Mandelli,et al. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial , 2006, Leukemia.
[2] E. Collisson,et al. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] M. Vignetti,et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. , 2005, Blood.
[4] F. Ferrara,et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. , 2005, Haematologica.
[5] J. Esteve,et al. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. , 2004, Haematologica.
[6] F. Ferrara,et al. Autologous stem‐cell transplantation for patients with acute myeloid leukemia aged over 60 yr , 2002, European journal of haematology.
[7] L. Balducci. The geriatric cancer patient: equal benefit from equal treatment. , 2001, Cancer control : journal of the Moffitt Cancer Center.
[8] F. Mandelli,et al. Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group , 2000, British journal of haematology.
[9] M. Labopin,et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells , 2000, British journal of haematology.
[10] W. Hiddemann,et al. Management of acute myeloid leukemia in elderly patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Mazza,et al. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report , 1999, Bone Marrow Transplantation.
[12] R. Willemze,et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia , 1999, Leukemia.
[13] J. Harousseau. Acute myeloid leukemia in the elderly. , 1998, Blood reviews.
[14] Keith Wheatley,et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.
[15] J. Román,et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome , 1998, Bone Marrow Transplantation.
[16] P. Hurteloup,et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1997, Blood.
[17] C. Sawyers,et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission , 1997, Leukemia.
[18] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[19] D. Blaise,et al. Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial , 1997, Annals of Internal Medicine.
[20] E. Ball,et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.
[21] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[22] P. Cony-Makhoul,et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. , 1996, Leukemia.
[23] F. Mandelli,et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.
[24] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[25] R. Zittoun,et al. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients , 1994, British journal of haematology.
[26] L. Schwartzberg,et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. , 1993, Bone marrow transplantation.
[27] C. Tangen,et al. A Southwest Oncology Group study , 1993 .
[28] L. To,et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. , 1992, Bone marrow transplantation.
[29] G. Kandel,et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. , 1992, Bone marrow transplantation.
[30] F. Mitelman. ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics , 1992 .
[31] H. Gralnick,et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.
[32] F. Mandelli,et al. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. , 1990, Blood.
[33] J. Matthews,et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.
[34] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[35] N. Nissen,et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.
[36] A. B. S T R. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old . Results of the CETLAM AML-99 , 2022 .